Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (trading symbol LNDC) on September 13, 2022. The filing addresses a corporate transition to Lifecore Biomedical, Inc. and a decision by the Audit Committee to no longer rely on previously issued unaudited financial statements for the periods ended February 27, 2022, and May 30, 2021.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it details a restatement of prior financial statements due to accounting corrections. The filing text does not provide a clear value for any specific financial metric.
Material Changes Versus Prior Period
The Audit Committee concluded that prior financial statements must be restated due to the following corrections:
- Expense Classification: Expenses related to disposition activities and the corporate transition to Lifecore Biomedical were previously classified as restructuring expenses from continuing operations. These will be reclassified as selling, general and administrative (SG&A) expenses and cost of goods sold within continuing operations.
- Transition Services Agreement (TSA): Net fees and costs from the TSA related to the sale of the Curation Foods' Eat Smart business were previously recognized as a loss on sale within discontinued operations. These will be corrected to classify TSA fees as transition services income and TSA costs as SG&A expenses within continuing operations.
- Discontinued Operations: Certain costs related to disposition activities and the corporate transition, previously classified as loss on sale of Eat Smart within discontinued operations, will be reclassified as SG&A expenses within continuing operations.
Guidance, Outlook, Risks, and Contingencies
Restatement Plan: The company intends to include restated unaudited interim financial statements in its Annual Report on Form 10-K for the fiscal year ended May 29, 2022, expected to be filed after the market close on September 13, 2022. No amended Form 10-Q will be filed for the third quarter ended February 27, 2022.
Internal Controls: The company expects to conclude in the 2022 Form 10-K that there was a material weakness in the design and operation of internal controls over the completeness and accuracy of accounting for non-standard transactions, specifically regarding discontinued operations and restructuring costs.
Risks: Forward-looking statements regarding the restatement are subject to risks, including the potential for additional information to emerge, the timing of the audit by Ernst & Young LLP, and the possibility that the filing of the 2022 Form 10-K may take longer than expected.
Important Facts for Investors to Verify
- Do not rely on previously issued unaudited consolidated balance sheets, statements of income, cash flows, or equity for periods ending February 27, 2022, and May 30, 2021.
- Wait for the upcoming 2022 Form 10-K for the restated financial figures and the final conclusion on the material weakness in internal controls.
- Verify the impact of reclassifying discontinued operations and restructuring costs into continuing operations on the company's reported profitability and segment performance.
- Monitor the filing timeline for the 2022 Form 10-K, as delays could indicate further complexities in the restatement process.